| Old Articles: <Older 6451-6460 Newer> |
|---|
 |
The Motley Fool
July 9, 2010
Brian Orelli |
Changing Pay-For-Delay Will Hurt Everyone Whether you're an investor in brand-name drugs or in companies that make generics, FTC chairman Jon Leibowitz is not your friend.   |
The Motley Fool
July 9, 2010
Ryan McBride |
Novartis Test-Drives Biotech Startup Adimab's Drug Discovery Engine More collaborations in Big Pharma. |
BusinessWeek
July 8, 2010
Simeon Bennett |
Pfizer: Civil Suits for Drug Counterfeiters Pfizer's new tactics against fake drug peddlers have allowed it to recoup more than $5 million. That's still a fraction of its lost sales. |
The Motley Fool
July 8, 2010
Brian Orelli |
Surprise Us in a Good Way, Merck Keeping up productivity during plant closures won't be easy. |
The Motley Fool
July 7, 2010
Dave Mock |
A Big Upgrade for Novartis This bullish call comes from more than just one analyst. |
The Motley Fool
July 7, 2010
Brian Orelli |
That's Gotta Hurt: Recommending the Competition Supply constraints continue to plague Genzyme. |
The Motley Fool
July 6, 2010
Luke Timmerman |
Rising From the Ashes of Pfizer: The Michigan Contract Research Organization Cluster Many of the people who honed their skills inside Pfizer and other big companies have found new entrepreneurial outlets to keep doing what they do best at a growing array of contract research organizations. |
The Motley Fool
July 6, 2010
Luke Timmerman |
Amazon Sees the Future of Biology in the Cloud Amazon Web Services is helping life sciences companies. |
The Motley Fool
July 2, 2010
Brian Orelli |
Arena Got Taken A billion-dollar market and that's all the pharmaceuticals company could get? |
BusinessWeek
July 1, 2010
Doherty & Waters |
Post-Buyout, Genentech's DNA Is Dominant Bought out for $47 billion, the biotech pioneer has gained the upper hand |
| <Older 6451-6460 Newer> Return to current articles. |
